title: Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy.
abstract: The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine Fβ2supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.
authors.affiliation: Laboratory of Molecular and Cellular Therapy; Department of Biomedical Sciences; Vrije Universiteit Brussel ; Jette, Belgium.
authors.forename: Kevin
authors.initials: K
authors.lastname: Van der Jeught
authors.affiliation: Laboratory of Molecular and Cellular Therapy; Department of Biomedical Sciences; Vrije Universiteit Brussel ; Jette, Belgium.
authors.forename: Sandra
authors.initials: S
authors.lastname: Van Lint
authors.affiliation: Laboratory of Molecular and Cellular Therapy; Department of Biomedical Sciences; Vrije Universiteit Brussel ; Jette, Belgium.
authors.forename: Kris
authors.initials: K
authors.lastname: Thielemans
authors.affiliation: Laboratory of Molecular and Cellular Therapy; Department of Biomedical Sciences; Vrije Universiteit Brussel ; Jette, Belgium.
authors.forename: Karine
authors.initials: K
authors.lastname: Breckpot
keywords: CD8+ T cell; CTLs, cytotoxic T lymphocytes; DCs, dendritic cells; Fβ2, a fusokine consisting of IFNβ, fused to the ectodomain of the TGFβ receptor II; IFNβ; IMP, investigational medicinal product; MDSCs, myeloid-derived suppressor cells; TAAs, tumor-associated antigens; TGFβ ; TME, tumor microenvironment; TiDCs, tumor-infiltrating DCs; cancer; dendritic cell; fusokine; immunotherapy; intratumoral; mRNA; receptor II